Is Unihealth Hosp overvalued or undervalued?

Valuation Metrics and Financial Health

Unihealth Hosp’s price-to-earnings (PE) ratio stands at 33.9, which, while elevated compared to many sectors, is relatively moderate within the healthcare industry. The price-to-book (P/B) value of 3.82 suggests that the market values the company at nearly four times its net asset value, reflecting investor confidence in its growth prospects. The enterprise value to EBITDA (EV/EBITDA) ratio of 13.3 further supports this moderate valuation, indicating the company is not excessively priced relative to its earnings before interest, taxes, depreciation, and amortisation.

Importantly, the PEG ratio of 0.94 is below 1, signalling that Unihealth Hosp’s price is reasonable relative to its earnings growth potential. This is a key indicator that the stock may be undervalued, especially when compared to peers with significantly higher PEG ratios. The company’s return on capital employed (ROCE) of 22.9% and return on equity (ROE) of 11.3% demonstrate efficient use of capital and shareholder funds, reinforcing the attractiveness of its valuation.

Peer Comparison Highlights

When compared to its industry peers, Unihealth Hosp’s valuation metrics stand out favourably. Several competitors, including Max Healthcare and Fortis Healthcare, are classified as very expensive, with PE ratios exceeding 60 and EV/EBITDA multiples well above 30. In contrast, Unihealth Hosp’s more modest multiples and attractive valuation grade suggest it is trading at a discount relative to these peers.

Apollo Hospitals, another attractive stock in the sector, has a PE ratio nearly double that of Unihealth Hosp and a PEG ratio of 1.5, indicating a pricier valuation relative to growth. This comparison underscores Unihealth Hosp’s potential as a value proposition within the hospital industry.

Market Performance and Price Trends

Unihealth Hosp’s stock price has demonstrated robust returns over recent periods, significantly outperforming the Sensex benchmark. Year-to-date, the stock has surged over 110%, compared to the Sensex’s 9.9% gain. Over the past year, the stock’s return of approximately 97.5% dwarfs the Sensex’s 6.3% rise, highlighting strong investor demand and confidence.

Despite a recent one-week dip of nearly 17%, this volatility is not uncommon in high-growth stocks and may present a buying opportunity. The stock’s 52-week high of ₹390.60 and low of ₹120.00 illustrate a wide trading range, but the current price near ₹309 remains well below the peak, suggesting room for appreciation.

Balancing Valuation with Growth Prospects

While Unihealth Hosp’s valuation multiples are higher than traditional value stocks, they are justified by the company’s solid growth metrics and efficient capital utilisation. The attractive valuation grade assigned recently reflects a market reassessment of the company’s future earnings potential and risk profile.

Investors should note the absence of a dividend yield, which is typical for growth-oriented healthcare companies reinvesting earnings into expansion. The company’s strong ROCE and ROE figures indicate that these reinvestments are likely generating value.

Conclusion: Undervalued Relative to Peers and Growth Potential

Considering the comprehensive data, Unihealth Hosp appears undervalued relative to its sector peers and its own growth trajectory. Its moderate PE and EV/EBITDA ratios, combined with a PEG ratio below 1, suggest the stock is reasonably priced for the earnings growth expected. The company’s superior returns compared to the Sensex further reinforce its investment appeal.

For investors seeking exposure to the hospital sector with a favourable risk-reward profile, Unihealth Hosp presents an attractive opportunity. However, as with all investments, it is prudent to monitor market conditions and company fundamentals continuously.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →